RSS  JOBS   SITE MAP 
 HOME 
PHARMA
BIO TECHNOLOGY
MEDICAL TECHNOLOGY
 RESOURCE CENTER 
 NEWSLETTER 
 DIGITAL MAGAZINE 
  Saturday, February 4, 2012 SEARCH     
BIO AUSTRALIA
BIO CHINA
BIO INDIA
BIO INDONESIA
BIO JAPAN
BIO KOREA
BIO MALAYSIA
BIO NEW ZEALAND
BIO PHILIPPINES
BIO SINGAPORE
BIO TAIWAN
BIO THAILAND

Australian Biotech and Pharmaceutical
PRIME NEWS
Mesoblast receives FDA clearance for ph II diabetes trial
Mesoblast has received clearance from the United States Food and Drug Administration to begin a Phase 2 clinical trial of its proprietary adult stem cells for the treatment of Type 2 diabetes
Immuron, Monash collaborate to develop C. difficile treatment products
Australian biopharmaceutical company Immuron has entered into a collaboration agreement with Monash University to develop a product aimed at both prevention and treatment of Clostridium difficile infections
TODAY'S NEWS
  Renaissance in genomics with next generation sequencing
  Starpharma releases animal data for dendrimer-docetaxel formulation
  PAREXEL collaborates with Korea's ASAN Medical
  CVS/pharmacy launches product for prescription text alerts
  FDA and industry agree on medical device user fees
  Prana comments on three scientific journal articles
Advertisement
 
Digital Mag

Issue: Jan 2012
Current Issue
View / Download
Top Story
Diabetes epidemic on the rise
 
 
 
Print Edition
Issue: Jan 2012
Read Online
Free Subscription
 
 
Get the latest news on life sciences in your mail box
Name
E-Mail Id
 
 
Advertisement

 

NEWS
Prana comments on three scientific journal articles
Prana Biotechnology commented on three recent high profile scientific journal articles that the company believes provide support for Pranas therapeutic strategy for treating neurodegenerative disease
Immuron, Monash collaborate to develop C. difficile treatment products
Australian biopharmaceutical company Immuron has entered into a collaboration agreement with Monash University to develop a product aimed at both prevention and treatment of Clostridium difficile infections
FEATURES
Study shows cancer incidence rates on rise in Australia
Over the past quarter century in Australia, cancer incidence rates have increased while deaths from cancer have steadily decreased. Those are some of the findings of a recent study published early online in the Asia-Pacific Journal of Clinical Oncolo
Trailblazers: Verva Pharmaceuticals in search of novel diabetes therapy
While pharmaceutical companies worldwide are looking for newer and safer insulin sensitizers to treat diabetes, Australia-based Verva Pharmaceuticals is working on a product candidate that promises to be an effective tool in controlling diabetes
PEOPLE
Xenome appoints independent board member
Biopharmaceutical company Xenome has appointed an independent board member Dr Julie Cherrington as chair of the board
Prof Rudy Tanzi appointed chief scientific adviser of Prana
Prana Biotechnology has appointed Professor Rudy Tanzi as the company's chief scientific advisor
EVENTS
Australia's thriving biotech industry showcased at BIO
Australia concluded a showcase of its scientists, innovative companies, projects and technology at the 2011 BIO International Convention
Queensland to spend $100 mn to boost biotech investments
To further strengthen its biotechnology sector, the State Government of Queensland, Australia has announced additions to the New Smart State Fund
R & D
Research shows link between temperature and still births
Research done at Queensland University of Technology (QUT) is the first to find a link between increases in temperature and the incidence of stillbirth and shorter pregnancies
$21.2 mn grant for University of Melbourne researchers
University of Melbourne researchers have received $21.2 million to assist with a range of projects, such as developing early health interventions by using prediction models and control of flu
POLICIES
Australia to reform TGA transparency
Australia prime minister, Julia Eileen Gillards government will introduce a comprehensive package of reforms for Australias TGA to ensure the regulation of medicines and medical devices is more effective and transparency.
IVD Australia disappointed by TGA Blueprint
IVD Australia has expressed its disappointment in the lack of commitment shown by the Government to increasing the level of ethical standards in the promotion of health sector products.
PRODUCTS
Universal Biosensor's OneTouch VerioTM system launched in the US
Universal Biosensors announced that LifeScan has launched the OneTouch VerioTM IQ system in the US
Australia to develop youth depression monitor
Australian researchers will for the first time harness e-technology to develop a customised internet program to identify and arm healthy young people most at risk of depression before the disorder takes hold
TRENDS & ANALYSIS
Cellestis leverages on diagnostics and low overheads
The magnitude of QuantiFERONs success was such that this technology seems to be one of the main factors that encouraged Qiagen to go ahead with the acquisition of Cellestis at the cost of $355 million
Phosphagenics to proceed with twice weekly oxycodone patch development
Based on the results of a physician survey commissioned by Phosphagenics and conducted in the US, the company has made the decision to commercialise its oxycodone patch to be administered twice weekly for the management of chronic pain
 
Advertisement











 
Google
BioSpectrumAsia.com BioSpectrumIndia.com Web

About BioSpectrum | How to Advertise | Jobs at BioSpectrum | Jobs at CyberMedia | Contact Us | Privacy Statement



CyberMedia Network Websites


[Voice&Data]  [PCQuest]  [CIOL]  [Dataquest]  [Living Digital]  [IDC India]
[DQ Channels]  [The DQweek]  [DARE]  
[CyberMedia Events] [CyberMedia Digital]  [Cyber Astro]  [CyberMedia India]  [Global Services]  [BioSpectrum]

 
Copyrights are reserved for BioSpectrum ; Designed by : Altered Black